Every material Form 8-K Vaxcyte, Inc. has filed with the SEC since October 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Vaxcyte reported a third-quarter 2026 net loss of $297.1 million, or $1.99 per share, up from $212.8 million, or $1.56 per share, a year earlier, as research and development expenses rose to $270.3 million. Cash, cash equivalents and investments were $2,264.4 million at September 30, 2026, and the company says about $1.1 billion in net proceeds from October 2026 offerings is not included in that figure, bringing pro forma cash to about $3.4 billion. The release also reports positive topline data from the OPUS-1 Phase 3 trial of VAX-31 in adults, which shareholders will weigh against the higher spending.
Net loss was $297.1 million ($1.99 per share) for the quarter ended September 30, 2026, versus $212.8 million ($1.56 per share) a year earlier.
R&D expenses were $270.3 million versus $209.9 million, driven mainly by VAX-31 OPUS Phase 3 trials and manufacturing costs.
October 2026 offerings generated $1.15 billion in gross proceeds and about $1.1 billion in net proceeds; pro forma cash is about $3.4 billion.
OPUS-2 and OPUS-3 Phase 3 results are expected in the first half of 2027, with a BLA submission planned for the first half of 2028.
On October 9, 2026, Vaxcyte closed the sale of $575 million of 1.50% convertible senior notes due 2032, including an over-allotment option exercised in full, and a separate equity offering of 7,412,500 shares at $64.00 each plus pre-funded warrants. The filing reports net proceeds of approximately $558.7 million from the notes and $544.3 million from the equity offering, and notes that conversion of the notes would be settled in cash, shares, or a mix at Vaxcyte's election, which could dilute shareholders if shares are issued.
Convertible notes: $575 million principal, 1.50% interest, maturing October 15, 2032, with an initial conversion price of approximately $89.60 per share
Equity offering: 7,412,500 shares at $64.00 per share plus 400,000 pre-funded warrants, with a 1,171,875-share option exercised in full on October 7, 2026
Approximate net proceeds: $558.7 million from the notes and $544.3 million from the equity offering, after underwriting discounts and expenses
Both offerings were underwritten by Jefferies LLC and Leerink Partners LLC and closed on October 9, 2026
Vaxcyte said its pivotal Phase 3 OPUS-1 adult trial met all prespecified primary endpoints for VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, compared with Prevnar 20 and Capvaxive. The company said the results will serve as the cornerstone of a planned Biologics License Application to the FDA, with results from OPUS-2 and OPUS-3 expected in the first half of 2027. The filing contains no revenue, earnings or cash figures, and the data remain subject to FDA review.
All 28 VAX-31 serotypes shared with PCV20 and/or PCV21 met the noninferiority criterion in adults 50 and older.
VAX-31 met noninferiority for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21; serotypes 3 and 12F missed the stricter criterion against PCV21.
OPUS-2 and OPUS-3 results are expected in the first half of 2027, and a Biologics License Application submission is planned for the first half of 2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Vaxcyte, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →